Examples include ongoing preclinical and (pilot) patient studies evaluating the potential benefits of radio-guided surgery for the detection of neuroendocrine tumor and prostate cancer lesions using somatostatin receptor-targeting and prostate-specific membrane antigen-targeting radiotracers [19–24]. The gene discussed is FOLH1; the disease is Familial prostate cancer.